Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

NICE knocks back J&J’s depression nasal spray Spravato

NICE knocks back J&J’s depression nasal spray Spravato

Hitting back at the critics, director of real-world value and evidence at J&J’s Janssen Scientific Affairs unit John Sheenan said last year: "We found that, because it can

Latest news

More from news
Approximately 132 fully matching, plus 380 partially matching documents found.

Latest Intelligence

  • The first, my last, my everything The first, my last, my everything

    It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Katrin Haeverans, EPAD LCS and POC platform support, Janssen said: “EPAD has been built to facilitate proof-of-concept trials. ... Sir Simon Lovestone. After 18 years in old age psychiatry and dementia research in academia, Sir Simon Lovestone joined

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on.

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    Gilead’s HIV work continues apace as does that of rivals GSK, Sanofi, Janssen and others in a global HIV drug market expected to reach a value of $26, 458bn in

More from intelligence
Approximately 5 fully matching, plus 49 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics